Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
BicycleTx Limited
Bolt Biotherapeutics, Inc.
Memgen, Inc.
Incyte Corporation
DEKA Biosciences
University Hospital, Ghent
Fate Therapeutics
Fate Therapeutics
Jules Bordet Institute
Five Prime Therapeutics, Inc.